Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radio-guided lymph node dissection in oligometastatic prostate cancer
2019-003284-21Phase 2Active
- Sponsor
- Radboudumc
- Start
- Dec 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 111In-PSMA I&T in prostate cancer (PCa), sponsored by Radboudumc. Primary endpoint: Threshold of absolute gamma counts for tumor-positive lymph node identification. Started Dec 2019; status: active.
02
Drugs
111In-PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-003284-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003284-21.